Baidu
map

NEJM:局限性前列腺癌接受前列腺根治术可显著延长生存期

2018-12-13 zhangfan MedSci原创

研究发现,局限性前列腺癌接受前列腺根治术可显著延长生存期, Gleason评分和囊外扩张是预测患者预后的重要因素

根治性前列腺切除术可降低局限性前列腺癌患者的死亡率,但其长期疗效尚缺乏有效的随访研究。

1989-1999年间,695名观察等待或接受根治性前列腺切除术的局部前列腺癌的男性参与本次研究,随访至2017年。研究的主要终点全因死亡、前列腺癌死亡以及转移。

截止2017年底,347名接受手术的患者中261人死亡,348名观察等待的患者中292人死亡,其中手术组以及观察组死于前列腺的患者数分别为71和110人(RR=0.55)。23年间,手术组患者的寿命平均延长2.9年。在接受手术的人群中,囊外扩张人群的前列腺癌的死亡风险是非囊外扩展人群的5倍,Gleason得分7以上人群的死亡风险是6以下人群的10倍。

研究发现,局限性前列腺癌接受前列腺根治术可显著延长生存期, Gleason评分和囊外扩张是预测患者预后的重要因素。

原始出处:

Anna Bill-Axelson et al. Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up.N Engl J Med, December 13, 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1924034, encodeId=044319240344f, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Nov 09 18:40:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355475, encodeId=9fa03554e5bc, content=Nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db792503889, createdName=124a5940m50暂无昵称, createdTime=Sat Dec 15 09:21:39 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378199, encodeId=527c13e819923, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399726, encodeId=02801399e2600, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460470, encodeId=f41614604e0c0, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586124, encodeId=ec5f1586124d6, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355393, encodeId=b6d5355393ef, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Dec 14 13:10:16 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355308, encodeId=d58a35530869, content=前列腺癌还是个热点啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/24/d9d14db78de202d73276f47d8d8e2596.jpg, createdBy=3b682249905, createdName=盖伦, createdTime=Thu Dec 13 13:49:28 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355306, encodeId=3d42355306b8, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Dec 13 12:45:43 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355299, encodeId=107c35529928, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Dec 13 12:05:31 CST 2018, time=2018-12-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1924034, encodeId=044319240344f, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Nov 09 18:40:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355475, encodeId=9fa03554e5bc, content=Nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db792503889, createdName=124a5940m50暂无昵称, createdTime=Sat Dec 15 09:21:39 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378199, encodeId=527c13e819923, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399726, encodeId=02801399e2600, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460470, encodeId=f41614604e0c0, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586124, encodeId=ec5f1586124d6, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355393, encodeId=b6d5355393ef, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Dec 14 13:10:16 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355308, encodeId=d58a35530869, content=前列腺癌还是个热点啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/24/d9d14db78de202d73276f47d8d8e2596.jpg, createdBy=3b682249905, createdName=盖伦, createdTime=Thu Dec 13 13:49:28 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355306, encodeId=3d42355306b8, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Dec 13 12:45:43 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355299, encodeId=107c35529928, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Dec 13 12:05:31 CST 2018, time=2018-12-13, status=1, ipAttribution=)]
    2018-12-15 124a5940m50暂无昵称

    Nice

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1924034, encodeId=044319240344f, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Nov 09 18:40:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355475, encodeId=9fa03554e5bc, content=Nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db792503889, createdName=124a5940m50暂无昵称, createdTime=Sat Dec 15 09:21:39 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378199, encodeId=527c13e819923, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399726, encodeId=02801399e2600, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460470, encodeId=f41614604e0c0, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586124, encodeId=ec5f1586124d6, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355393, encodeId=b6d5355393ef, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Dec 14 13:10:16 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355308, encodeId=d58a35530869, content=前列腺癌还是个热点啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/24/d9d14db78de202d73276f47d8d8e2596.jpg, createdBy=3b682249905, createdName=盖伦, createdTime=Thu Dec 13 13:49:28 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355306, encodeId=3d42355306b8, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Dec 13 12:45:43 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355299, encodeId=107c35529928, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Dec 13 12:05:31 CST 2018, time=2018-12-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1924034, encodeId=044319240344f, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Nov 09 18:40:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355475, encodeId=9fa03554e5bc, content=Nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db792503889, createdName=124a5940m50暂无昵称, createdTime=Sat Dec 15 09:21:39 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378199, encodeId=527c13e819923, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399726, encodeId=02801399e2600, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460470, encodeId=f41614604e0c0, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586124, encodeId=ec5f1586124d6, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355393, encodeId=b6d5355393ef, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Dec 14 13:10:16 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355308, encodeId=d58a35530869, content=前列腺癌还是个热点啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/24/d9d14db78de202d73276f47d8d8e2596.jpg, createdBy=3b682249905, createdName=盖伦, createdTime=Thu Dec 13 13:49:28 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355306, encodeId=3d42355306b8, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Dec 13 12:45:43 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355299, encodeId=107c35529928, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Dec 13 12:05:31 CST 2018, time=2018-12-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1924034, encodeId=044319240344f, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Nov 09 18:40:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355475, encodeId=9fa03554e5bc, content=Nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db792503889, createdName=124a5940m50暂无昵称, createdTime=Sat Dec 15 09:21:39 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378199, encodeId=527c13e819923, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399726, encodeId=02801399e2600, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460470, encodeId=f41614604e0c0, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586124, encodeId=ec5f1586124d6, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355393, encodeId=b6d5355393ef, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Dec 14 13:10:16 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355308, encodeId=d58a35530869, content=前列腺癌还是个热点啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/24/d9d14db78de202d73276f47d8d8e2596.jpg, createdBy=3b682249905, createdName=盖伦, createdTime=Thu Dec 13 13:49:28 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355306, encodeId=3d42355306b8, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Dec 13 12:45:43 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355299, encodeId=107c35529928, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Dec 13 12:05:31 CST 2018, time=2018-12-13, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1924034, encodeId=044319240344f, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Nov 09 18:40:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355475, encodeId=9fa03554e5bc, content=Nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db792503889, createdName=124a5940m50暂无昵称, createdTime=Sat Dec 15 09:21:39 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378199, encodeId=527c13e819923, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399726, encodeId=02801399e2600, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460470, encodeId=f41614604e0c0, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586124, encodeId=ec5f1586124d6, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355393, encodeId=b6d5355393ef, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Dec 14 13:10:16 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355308, encodeId=d58a35530869, content=前列腺癌还是个热点啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/24/d9d14db78de202d73276f47d8d8e2596.jpg, createdBy=3b682249905, createdName=盖伦, createdTime=Thu Dec 13 13:49:28 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355306, encodeId=3d42355306b8, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Dec 13 12:45:43 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355299, encodeId=107c35529928, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Dec 13 12:05:31 CST 2018, time=2018-12-13, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1924034, encodeId=044319240344f, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Nov 09 18:40:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355475, encodeId=9fa03554e5bc, content=Nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db792503889, createdName=124a5940m50暂无昵称, createdTime=Sat Dec 15 09:21:39 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378199, encodeId=527c13e819923, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399726, encodeId=02801399e2600, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460470, encodeId=f41614604e0c0, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586124, encodeId=ec5f1586124d6, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355393, encodeId=b6d5355393ef, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Dec 14 13:10:16 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355308, encodeId=d58a35530869, content=前列腺癌还是个热点啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/24/d9d14db78de202d73276f47d8d8e2596.jpg, createdBy=3b682249905, createdName=盖伦, createdTime=Thu Dec 13 13:49:28 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355306, encodeId=3d42355306b8, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Dec 13 12:45:43 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355299, encodeId=107c35529928, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Dec 13 12:05:31 CST 2018, time=2018-12-13, status=1, ipAttribution=)]
    2018-12-14 1ddf0692m34(暂无匿称)

    学习了谢谢分享

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1924034, encodeId=044319240344f, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Nov 09 18:40:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355475, encodeId=9fa03554e5bc, content=Nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db792503889, createdName=124a5940m50暂无昵称, createdTime=Sat Dec 15 09:21:39 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378199, encodeId=527c13e819923, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399726, encodeId=02801399e2600, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460470, encodeId=f41614604e0c0, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586124, encodeId=ec5f1586124d6, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355393, encodeId=b6d5355393ef, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Dec 14 13:10:16 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355308, encodeId=d58a35530869, content=前列腺癌还是个热点啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/24/d9d14db78de202d73276f47d8d8e2596.jpg, createdBy=3b682249905, createdName=盖伦, createdTime=Thu Dec 13 13:49:28 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355306, encodeId=3d42355306b8, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Dec 13 12:45:43 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355299, encodeId=107c35529928, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Dec 13 12:05:31 CST 2018, time=2018-12-13, status=1, ipAttribution=)]
    2018-12-13 盖伦

    前列腺癌还是个热点啊

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1924034, encodeId=044319240344f, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Nov 09 18:40:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355475, encodeId=9fa03554e5bc, content=Nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db792503889, createdName=124a5940m50暂无昵称, createdTime=Sat Dec 15 09:21:39 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378199, encodeId=527c13e819923, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399726, encodeId=02801399e2600, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460470, encodeId=f41614604e0c0, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586124, encodeId=ec5f1586124d6, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355393, encodeId=b6d5355393ef, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Dec 14 13:10:16 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355308, encodeId=d58a35530869, content=前列腺癌还是个热点啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/24/d9d14db78de202d73276f47d8d8e2596.jpg, createdBy=3b682249905, createdName=盖伦, createdTime=Thu Dec 13 13:49:28 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355306, encodeId=3d42355306b8, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Dec 13 12:45:43 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355299, encodeId=107c35529928, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Dec 13 12:05:31 CST 2018, time=2018-12-13, status=1, ipAttribution=)]
    2018-12-13 一个字-牛

    学习了谢谢分享

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1924034, encodeId=044319240344f, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Nov 09 18:40:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355475, encodeId=9fa03554e5bc, content=Nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db792503889, createdName=124a5940m50暂无昵称, createdTime=Sat Dec 15 09:21:39 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378199, encodeId=527c13e819923, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399726, encodeId=02801399e2600, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460470, encodeId=f41614604e0c0, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586124, encodeId=ec5f1586124d6, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355393, encodeId=b6d5355393ef, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Dec 14 13:10:16 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355308, encodeId=d58a35530869, content=前列腺癌还是个热点啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/24/d9d14db78de202d73276f47d8d8e2596.jpg, createdBy=3b682249905, createdName=盖伦, createdTime=Thu Dec 13 13:49:28 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355306, encodeId=3d42355306b8, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Dec 13 12:45:43 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355299, encodeId=107c35529928, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Dec 13 12:05:31 CST 2018, time=2018-12-13, status=1, ipAttribution=)]
    2018-12-13 kafei

    学习学习谢谢

    0

相关资讯

JCO:无转移生存率是局限性前列腺癌总生存率的有力替代物

众所周知中危与高危局限性前列腺癌的辅助治疗减少这种疾病的死亡人数。总生存率(OS)的替代指标可以加快新辅助疗法的评价。

NEJM:局限性前列腺癌患者,接受哪种治疗方法更好?

目前,通过前列腺特异性抗原(PSA)检测的前列腺癌治疗效果的比较仍然不确定。研究人员比较了主动监测,前列腺癌根治术,以及外照射放疗用于治疗临床局限性前列腺癌的治疗效果。在1999年至2009年间,共有82429名50至69岁的男性接受了PSA测试; 2664名参与者被诊断为局限性前列腺癌,共有1643名参与者同意接受随机化的主动监测(545人),外科手术(553),或放疗(545)。主要成果是平均

NEJM:转移性前列腺癌DNA-修复基因突变率远高于局部前列腺癌

DNA-修复基因如BRCA2的基因突变与致命性前列腺癌的发病风险增加相关。虽然局部前列腺癌患者的DNA修复基因突变的发生率是不足以保证常规检测,但是转移性前列腺癌患者的这种基因突变的频率尚未确定。 研究共纳入692名转移性前列腺癌患者,分离生殖细胞的DNA,并使用多重测序分析来评估在20个DNA修复基因与常染色体显性遗传性癌症易感综合征相关的突变。 结果,82名男性(11.8%)中共发

Eur Urol:不同的初次治疗方案对局限性前列腺癌患者术后生存质量影响的系统评价。

对于临床局限性前列腺癌,目前循证管理包括主动监测、手术、外放射治疗(EBRT)和近距离放疗。不同的治疗方式对生活质量(QOL)的影响是不确定的。

2018 ASTRO指南:局限性前列腺癌大分割放射治疗(概要)

2018年10月,美国放射治疗及肿瘤学会(ASTRO)发布了局限性前列腺癌大分割放射治疗指南,主要目的是针对适度的大分割(240-340 cGy 每部分)超大分割 (500 cGy 或更多每部分) 放疗治疗局限性前列腺癌提供指导建议。

Eur Uro:中/高风险局限性前列腺癌最终治疗的种族差异:设施特征和社会经济特征的影响。

过去十年来,前列腺癌 (PCa) 生存率在黑人与白人之间的差距扩大了。研究人员推测,这种差异可能部分归因于种族间最终治疗率(放射治疗或外科治疗)的差异。

Baidu
map
Baidu
map
Baidu
map